JP5713511B2 - ロイコトリエン産生のオキサジアゾール阻害剤 - Google Patents

ロイコトリエン産生のオキサジアゾール阻害剤 Download PDF

Info

Publication number
JP5713511B2
JP5713511B2 JP2013530221A JP2013530221A JP5713511B2 JP 5713511 B2 JP5713511 B2 JP 5713511B2 JP 2013530221 A JP2013530221 A JP 2013530221A JP 2013530221 A JP2013530221 A JP 2013530221A JP 5713511 B2 JP5713511 B2 JP 5713511B2
Authority
JP
Japan
Prior art keywords
alkyl
substituted
independently
cyclobutyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013530221A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013537909A (ja
Inventor
アレッサンドラ バルトロッツィ
アレッサンドラ バルトロッツィ
トッド ボサナック
トッド ボサナック
ジードン チェン
ジードン チェン
ロンベール ステファーヌ ドゥ
ロンベール ステファーヌ ドゥ
ジョナソン アラン ダインズ
ジョナソン アラン ダインズ
ジョン ディー フーバー
ジョン ディー フーバー
リウ　ウェイミン
ウェイミン リウ
プイ レン ローク
プイ レン ローク
モーウィック　ティナ　マリー
ティナ マリー モーウィック
アラン オラグ
アラン オラグ
ドリス リーター
ドリス リーター
ヘザー タイ
ヘザー タイ
リーフェン ウー
リーフェン ウー
レニー エム ジンデル
レニー エム ジンデル
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44720163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5713511(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング, ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2013537909A publication Critical patent/JP2013537909A/ja
Application granted granted Critical
Publication of JP5713511B2 publication Critical patent/JP5713511B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2013530221A 2010-09-23 2011-09-20 ロイコトリエン産生のオキサジアゾール阻害剤 Active JP5713511B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38573310P 2010-09-23 2010-09-23
US61/385,733 2010-09-23
US201161533349P 2011-09-12 2011-09-12
US61/533,349 2011-09-12
PCT/US2011/052254 WO2012040139A1 (en) 2010-09-23 2011-09-20 Oxadiazole inhibitors of leukotriene production

Publications (2)

Publication Number Publication Date
JP2013537909A JP2013537909A (ja) 2013-10-07
JP5713511B2 true JP5713511B2 (ja) 2015-05-07

Family

ID=44720163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013530221A Active JP5713511B2 (ja) 2010-09-23 2011-09-20 ロイコトリエン産生のオキサジアゾール阻害剤

Country Status (19)

Country Link
US (1) US8575201B2 (enExample)
EP (1) EP2619197B1 (enExample)
JP (1) JP5713511B2 (enExample)
KR (1) KR20130109122A (enExample)
CN (1) CN103261193A (enExample)
AU (1) AU2011305667A1 (enExample)
BR (1) BR112013008638A2 (enExample)
CA (1) CA2812449A1 (enExample)
CL (1) CL2013000788A1 (enExample)
CO (1) CO6710902A2 (enExample)
EA (1) EA201300389A1 (enExample)
EC (1) ECSP13012548A (enExample)
IN (1) IN2013DN02555A (enExample)
MX (1) MX2013003202A (enExample)
PE (1) PE20131398A1 (enExample)
PH (1) PH12013500545A1 (enExample)
SG (1) SG188604A1 (enExample)
WO (1) WO2012040139A1 (enExample)
ZA (1) ZA201301747B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3150164B2 (ja) 1991-05-01 2001-03-26 電気化学工業株式会社 セメント混和材及びセメント組成物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012027322A1 (en) * 2010-08-26 2012-03-01 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
EP2619196B1 (en) * 2010-09-23 2015-09-16 Boehringer Ingelheim International GmbH Oxadiazole inhibitors of leukotriene production
EA201300389A1 (ru) 2010-09-23 2013-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Оксадиазольные ингибиторы продуцирования лейкотриена
AR089853A1 (es) 2012-02-01 2014-09-24 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
EP3495359A1 (en) * 2013-02-04 2019-06-12 Janssen Pharmaceutica NV Flap modulators
EP2875736B1 (en) 2013-11-26 2016-07-27 Citrage N-Carbamoylputrescine to enhance muscle protein synthesis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2260031T3 (es) 1999-08-06 2006-11-01 Janssen Pharmaceutica N.V. Derivados de 6-azauracilo que inhiben la interleucina-5.
JP2007502300A (ja) * 2003-08-13 2007-02-08 カイロン　コーポレイション Ｇｓｋ−３インヒビターおよびその使用
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
AU2005295646B2 (en) 2004-10-18 2008-11-20 Merck Sharp & Dohme Corp. Diphenyl substituted alkanes as flap inhibitors
US7977359B2 (en) * 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) * 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
AU2007238878A1 (en) 2006-04-11 2007-10-25 Merck Sharp & Dohme Corp. Diaryl substituted alkanes
CA2787343C (en) 2006-06-26 2016-08-02 Amgen Inc. Compositions comprising modified lcat and uses thereof
ATE543810T1 (de) 2006-09-01 2012-02-15 Merck Sharp & Dohme Hemmer des 5-lipoxygenase aktivierenden proteins (flap)
AU2008241313A1 (en) 2007-04-20 2008-10-30 Merck Frosst Canada Ltd. Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
CA2707360A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Diphenyl substituted alkanes
WO2009048547A1 (en) 2007-10-10 2009-04-16 Merck & Co., Inc. Diphenyl substituted cycloalkanes
DE102008037790A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
CA2741666C (en) * 2008-10-31 2017-04-11 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
CA2749893A1 (en) 2009-02-04 2010-08-12 Pfizer Inc. 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives
EP2568809A4 (en) 2010-05-12 2013-11-06 Univ Vanderbilt HETEROCYCLIC ALLOSTERE SULFON MGLUR4 POTENTIATORS, COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS
PH12013500301A1 (en) * 2010-08-16 2013-03-25 Boehringer Ingelheim Int Oxadiazole inhibitors of leukotriene production
WO2012027322A1 (en) * 2010-08-26 2012-03-01 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
EA201300389A1 (ru) 2010-09-23 2013-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Оксадиазольные ингибиторы продуцирования лейкотриена
EP2619196B1 (en) * 2010-09-23 2015-09-16 Boehringer Ingelheim International GmbH Oxadiazole inhibitors of leukotriene production

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3150164B2 (ja) 1991-05-01 2001-03-26 電気化学工業株式会社 セメント混和材及びセメント組成物

Also Published As

Publication number Publication date
WO2012040139A1 (en) 2012-03-29
ECSP13012548A (es) 2013-06-28
KR20130109122A (ko) 2013-10-07
EA201300389A1 (ru) 2013-09-30
CA2812449A1 (en) 2012-03-29
EP2619197B1 (en) 2015-08-05
US8575201B2 (en) 2013-11-05
AU2011305667A1 (en) 2013-03-21
ZA201301747B (en) 2014-08-27
CO6710902A2 (es) 2013-07-15
MX2013003202A (es) 2013-04-24
JP2013537909A (ja) 2013-10-07
IN2013DN02555A (enExample) 2015-08-07
EP2619197A1 (en) 2013-07-31
PH12013500545A1 (en) 2013-05-06
CN103261193A (zh) 2013-08-21
BR112013008638A2 (pt) 2016-06-21
SG188604A1 (en) 2013-04-30
PE20131398A1 (es) 2013-12-19
CL2013000788A1 (es) 2013-06-28
US20120295896A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
JP5862669B2 (ja) ロイコトリエン産生のオキサジアゾール阻害剤
JP5444365B2 (ja) 抗癌活性および抗増殖活性を示すシクロプロパンアミドおよび類似物質
CN104662018B (zh) 取代的杂双环化合物、组合物及其医疗应用
CN105764514B (zh) 作为tam族激酶抑制剂的氨基吡啶衍生物
EP2606045B1 (en) Oxadiazole inhibitors of leukotriene production
JP5690839B2 (ja) ロイコトリエン産生のベンゾイミダゾール阻害薬
JPWO2007116866A1 (ja) ヘテロ化合物
JPWO2010013849A1 (ja) Ｇｐｒ１１９作動薬
ES2651484T3 (es) Compuesto heterocíclico que contiene nitrógeno
CN105339368A (zh) 3-芳基-取代的咪唑并[1,2-a]吡啶及其用途
EP2809321B1 (en) Phenyl-c-oxadiazole derivatives as inhibitors of leukotriene production for use in combination therapy
JP2013537909A (ja) ロイコトリエン産生のオキサジアゾール阻害剤
KR20150054994A (ko) 브루톤 티로신 키나아제의 억제제
JP5828188B2 (ja) ロイコトリエン産生のオキサジアゾール阻害剤
JP2009542642A (ja) 新規ピリジン類似体
JP2009542643A (ja) 新規ピリジン類似体
EA021015B1 (ru) Индазолы и пиразолопиридины в качестве антагонистов рецептора ccr1
JP2012502035A (ja) ロイコトリエン産生のインドリジン阻害剤
HK1183300A (en) Oxadiazole inhibitors of leukotriene production
OA16344A (en) Oxadiazole inhibitors of leukotriene production.
HK1182389A (en) Oxadiazole inhibitors of leukotriene production

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130522

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140916

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150309

R150 Certificate of patent or registration of utility model

Ref document number: 5713511

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250